Tailored therapy for severe asthma

Multidisciplinary Respiratory Medicine

Volumn 10, Issue 1, 2015, Pages

  Menzella, Francesco ^a   Lusuardi, Mirco ^b   Galeone, Carla ^a   Zucchi, Luigi ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b PATHOLOGY UNIT   (Italy)

Author keywords

Asthma; COPD; Cytokines; Inflammation; Monoclonal antibodies

Indexed keywords

BENRALIZUMAB; BETA INTERFERON; CANAKINUMAB; CD33 ANTIGEN; CHEMOKINE RECEPTOR CCR4; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DACLIZUMAB; ECULIZUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; LEBRIKIZUMAB; LIGELIZUMAB; LUMILIXIMAB; MEPOLIZUMAB; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; RESLIZUMAB; SNG 001; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; CLINICAL EFFECTIVENESS; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOEFFLER PNEUMONIA; NONHUMAN; NOSE POLYP; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; TREATMENT RESPONSE;

EID: 84938060732     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-10-1     Document Type: Review

References (63)

1. Payne DN, Rogers AV, Adelroth E, Bandi V., Guntupalli KK, Bush A, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Resp Crit Care Med. 2003;167:78-82.
2. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804-13.
3. Simpson JL, Scott R, Boyle M.J., Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54-61.
4. Woodruff PG, Modrek B, Choy D.F., Jia G., Abbas AR, Ellwanger A, et al. T-helper type2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388-95.
5. Kim MA, Shin YS, le Pham D, Park HS. Adult asthma biomarkers. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
6. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28-35.
7. Lowe PJ, Tannenbaum S, Gautier A., Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol. 2009;68:61-76.
8. Hanania NA, Wenzel S, Rosén K, Hsieh H.J., Mosesova S., Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-11.
9. Ames SA, Gleeson CD, Kirkpatrick P. Omalizumab. Nat Rev Drug Discov. 2004;3(3):199-200.
10. Menzella F, Piro R, Facciolongo N., Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011;7(1):9.
11. Forester JP, Calabria CW Local production of IgE in the respiratory mucosa and the concept of entopy: does allergy exist in nonallergic rhinitis? Ann Allergy Asthma Immunol. 2010;105(4):249-55
12. Busse WW, Morgan WJ, Gergen P.J., Mitchell HE, Gern JE, Liu AH, et al Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005-15.
13. de Groot E.P., Duiverman EJ, Brand PL Comorbidities of asthma during childhood: possibly important, yet poorly studied. Eur Respir J. 2010;36:671-8.
14. Morjaria JB, Polosa R. Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Rev Respir Med. 2009;3:299-308.
15. Giavina-Bianchi P., Agondi R, Kalil J. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol 2008;146(2):176.
16. Giavina-Bianchi P., Giavina-Bianchi M, Agondi R., Kalil J. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol. 2008;122(1):217.
17. Kaya H, Gümüj S, Uçar E, Aydoʇan M, Mujabak U, Tozkoparan E, et al. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia Chest. 2012;142(2):513-6
18. Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408-16.
19. Nopp A, Johansson SG, Adédoyin J, Ankerst J., Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56-60
20. Pace E, Ferraro M, Bruno A., Chiappara G, Bousquet J, Giomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma. 2011;48(4):387-92.
21. Menzella F, Facciolongo N, Piro R., Formisano D, Roggeri A, Simonazzi A., et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis. 2012;6(2):87-95.
22. Dal Negro R.W., Pradelli L, Tognella S., Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45-53
23. Polosa R, Casale T. Monoclonal antibodies for chronic refractory asthma and pipeline developments. Drug Discovery Today. 2013;17:591-9.
24. Byrd JC, O'Brien S, Flinn IW, Kipps T.J., Weiss M., Rai K, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:4448-55.
25. Bach JF. Regulatory T, cells under scrutiny. Nat Rev Immunol. 2003;3(3):189-98.
26. Shalev I, Schmelzle M, Robson S.C., Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol. 2011;23(4):282-92.
27. Busse WW, Israel E, Nelson H.S., Baker JW, Charous BL, Young DY, et al Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-8.
28. Gauvreau GM, Boulet LP, Cockcroft D.W., Fitzgerald JM, Carlsten C, Davis BE, et al Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011; 183(8):1007-14
29. Corren J, Lemanske RF, Hanania N.A., Korenblat PE, Parsey MV, Arron JR, et al Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365(12):1088-98.
30. Uhm TG, Kim BS, Chung IY Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res. 2012;4(2):68-79.
31. Kouro T, Takatsu K IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009 21(12):1303-9.
32. Tanaka H, Komai M, Nagao K., Ishizaki M, Kajiwara D, Takatsu K., et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol. 200431(1):62-8.
33. Rothenberg ME, Klion AD, Roufosse F.E., Kahn JE, Weller PF, Simon HU, et al Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008358(12):1215-28.
34. Kim S, Marigowda G, Oren E., Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336-43
35. Haldar P, Brightling CE, Hargadon B, Gupta S., Monteiro W, Sousa A, et al Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973-84.
36. Pavord ID, Korn S, Howarth P., Bleecker ER, Buhl R, Keene ON, et al Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9.
37. McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? Am J Respir Crit Care Med. 2011;184(10):1096-7.
38. Bel EH, Wenzel SE, Thompson P.J., Prazma CM, Keene ON, Yancey SW, et al Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-97.
39. Ortega HG, Liu MC, Pavord I.D., Brusselle GG, FitzGerald JM, Chetta A, et al Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207.
40. Castro M, Mathur S, Hargreave F., Boulet LP, Xie F, Young J, et al Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-32.
41. Busse WW, Katial R, Gossage D., Sari S, Wang B, Kolbeck R., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237-44.
42. Kolbeck R, Kozhich A, Koike M., Peng L, Andersson CK, Damschroder M.M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344-53.
43. Gauvreau GM, Boulet LP, Cockcroft D.W., Baatjes A., Cote J, Deschesnes F, et al Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177(9):952-8.
44. Subramaniam JM, Whiteside G, McKeage K., Croxtall JC. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293-8.
45. Knight DM, Trinh H, Le J., Siegel S, Shealy D, McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443-53.
46. Howarth PH, Babu KS, Arshad H.S., Lau L., Buckley M, McConnell W, et al Tumour necrosis factor (TNF-α) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60(12):1012-8.
47. Holgate ST, Noonan M, Chanez P., Busse W, Dupont L, Pavord I., et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011;37(6):1352-9.
48. Morjaria JB, Chauhan AJ, Babu K.S., Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008;63(7):584-91.
49. Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, et al. Monoclonal anti-TNF-α antibodies for severe steroid-dependent asthma: a case series. Open Respir Med J. 2013;7:21-5.
50. Erin EM, Leaker BR, Nicholson G.C., Tan AJ, Green LM, Neighbour H, et al The effects of a monoclonal antibody directed against tumor necrosis factor in asthma. Am J Respir Crit Care Med. 2006;174(7):753-62.
51. Wenzel SE, Barnes PJ, Bleecker E.R., Bousquet J., Busse W, Dahlén SE, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549-58.
52. van der Vaart H, Koeter GH, Postma DS, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:465-9.
53. Suissa S, Ernst P, Hudson M. TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21:234-8.
54. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol. 2002; 65(Suppl):33-8.
55. Bongartz T, Sutton AJ, Sweeting M.J., Buchan I., Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85.
56. Smith SG, Watson B, Clark G., Gauvreau GM. Eculizumab for treatment of asthma. Expert Opin Biol Ther. 2012;12(4):529-37.
57. Dinarello CA. The Il-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20(27):S1-S13.
58. Dhimolea E. Canakinumab. MAbs. 2010;2(1):3-13.
59. Pascoe S, Kanniess F, Bonner J., Lloyd P, Lowe P, Beier J., et al. A monoclonal antibody to IL-1β attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Annu Congr Eur Resp Soc. 2006. Abs 752.
60. 2 LEN-DARE systematic review. Allergy. 2011;66(4):458-68.
61. Jackson DJ, Johnston SL The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol. 2010;125:1178-87.
62. Wark PA, Johnston SL, Bucchieri F, Powell R., Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201:937-47.
63. Djukanović R, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014;190(2):145-54.